NASDAQ:JUNO

Juno Therapeutics, Inc. develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory (r/r) B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); and JCAR014, which is in Phase I/II trials to treat B cell malignancies in patients relapsed or refractory to standard therapies. The company’s CD22 product candidate comprise JCAR018 that is in Phase I trial for pediatric and young adult patients with CD22-positive r/r ALL or r/r NHL. Its additional product candidates include CD171, a cell-surface adhesion molecule for neuroblastoma; Lewis Y for the treatment of lung cancer; JCAR023, which is in Phase I trial for refractory or recurrent pediatric neuroblastoma; MUC-16 protein for ovarian cancers; and IL-12, a cytokine to overcome the inhibitory effects. The company’s additional product candidates also comprise ROR-1 protein for non-small cell lung, triple negative breast, pancreatic, and prostate cancers; WT-1, an intracellular protein that is in Phase I/II clinical trials; HPV e6/e7 for cancers; and IL13ra2 for glioblastoma. Juno Therapeutics, Inc. has collaboration agreements with Celgene Corporation, Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, St. Jude Children’s Research Hospital/Novartis, Seattle Children’s Research Institute, Opus Bio, Inc., Fate Therapeutics, Inc., Editas Medicine, Inc., and JW (Cayman) Therapeutics Co., Ltd. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington. As of March 6, 2018, Juno Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.